Search
for
Sort by
Research 511–540 of 1000+
- Alopecia Areata Possibly Secondary to COVID-19 Vaccine
- Alopecia Areata: An Updated Review for 2023
- ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
- Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- Ritlecitinib in severe alopecia areata: a profile of its use
- FRI0157 OBSERVATIONAL STUDY OF HAIR FALL IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH LOW DOSE METHOTREXATE COMPARED TO HEALTHY CONTROLS
- Healing hair naturally: A case study of alopecia areata treated with individualized homeopathy
- Evaluation of Effectiveness of Bio-Micro Injection in Treating Alopecia Universalis: A Non-Randomized Interventional Study
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study
- 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins
- Tofacitinib for the treatment of alopecia areata and variants in adolescents
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- Efficacy and safety of tofacitinib in patients with alopecia areata
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Case Report: Bimekizumab for dissecting cellulitis of the scalp
- Fractional CO₂ laser combined with topical compound betamethasone for Vitiligo-Associated Leukotrichia: a retrospective study of 13 patients with limited effectiveness
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
- EFFECTS OF LIRAGLUTIDE ON VISCERAL ADIPOSITY INDEX IN WOMAN OF REPRODUCTIVE AGE WITH PREDIABETES
- Alopecia universalis treated with simvastatin/ezetimibe, minoxidil, and prednisolone in a 6‐year‐old girl
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA